{"id":10923,"date":"2025-06-24T14:22:10","date_gmt":"2025-06-24T14:22:10","guid":{"rendered":"https:\/\/www.europesays.com\/us\/10923\/"},"modified":"2025-06-24T14:22:10","modified_gmt":"2025-06-24T14:22:10","slug":"rare-mutation-shields-brain-from-alzheimers-by-silencing-inflammation","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/10923\/","title":{"rendered":"Rare Mutation Shields Brain from Alzheimer\u2019s by Silencing Inflammation"},"content":{"rendered":"<p><strong>Summary: <\/strong>A rare genetic mutation known as APOE3-R136S, or the \u201cChristchurch mutation,\u201d appears to protect against Alzheimer\u2019s disease by suppressing inflammatory signaling in the brain\u2019s immune cells. Researchers found that this mutation dampens the cGAS-STING pathway, a key innate immune mechanism that is abnormally activated in Alzheimer\u2019s and other neurodegenerative disorders.<\/p>\n<p>Mice engineered with the mutation showed less tau accumulation, synaptic damage, and brain dysfunction\u2014hallmarks of Alzheimer\u2019s\u2014despite having high amyloid levels. The findings suggest that targeting cGAS-STING could mimic the mutation\u2019s protective effects and offer a new route for treating Alzheimer\u2019s.<\/p>\n<p><strong>Key Facts:<\/strong><\/p>\n<ul class=\"wp-block-list\">\n<li><strong>Protective Pathway Identified:<\/strong> The Christchurch mutation suppresses cGAS-STING, a key immune pathway in Alzheimer\u2019s.<\/li>\n<li><strong>Drug Potential:<\/strong> Blocking this pathway in mice mirrored the mutation\u2019s protective effects on brain function.<\/li>\n<li><strong>Focus Shift:<\/strong> Findings support the idea that inflammation and tau\u2014not just amyloid\u2014drive Alzheimer\u2019s progression.<\/li>\n<\/ul>\n<p><strong>Source: <\/strong>Weill Cornell University<\/p>\n<p><strong>A rare gene mutation that delays Alzheimer\u2019s disease does so by damping inflammatory signaling in brain-resident immune cells, according to a preclinical study led by investigators at Weill Cornell Medicine. <\/strong><\/p>\n<p>The finding adds to growing evidence that brain inflammation is a major driver of neurodegenerative disorders such as Alzheimer\u2019s\u2014and that it may be a key therapeutic target for these disorders.<\/p>\n<p>  <img fetchpriority=\"high\" decoding=\"async\" width=\"1200\" height=\"799\" src=\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2025\/06\/genetics-inflammation-Alzheimers-neurosicne.jpg\" alt=\"This shows a brain.\"  \/> In the new study, Dr. Gan\u2019s team engineered the Christchurch mutation into the APOE gene in mice that develop tau accumulation, and found that it protected the animals from hallmark Alzheimer\u2019s features\u2014including tau accumulation, synaptic damage, and disruptions in brain. Credit: Neuroscience News<\/p>\n<p>In the study, published June 23 in\u00a0Immunity, the researchers examined the effects of the mutation APOE3-R136S\u2014known as the \u201cChristchurch mutation\u201d\u2014which was recently found to delay hereditary early-onset Alzheimer\u2019s.<\/p>\n<p>The Weill Cornell Medicine scientists showed that the mutation inhibits the cGAS-STING pathway, an innate immune signaling cascade that is abnormally activated in Alzheimer\u2019s and other neurodegenerative diseases.<\/p>\n<p>The researchers found that pharmacologically blocking the cGAS-STING pathway with a drug-like inhibitor replicated key protective effects of the mutation in a preclinical model.<\/p>\n<p>\u201cThis is an exciting study because it suggests that inhibiting this cGAS-STING pathway could make the brain more resistant to the Alzheimer\u2019s process, even in the face of significant tau accumulation,\u201d said study senior author Dr. Li Gan, the Burton P. and Judith B. Resnick Distinguished Professor in Neurodegenerative Diseases and director of the Helen and Robert Appel Alzheimer\u2019s Disease Research Institute at Weill Cornell Medicine.<\/p>\n<p>The study\u2019s co-first authors were Drs. Sarah Naguib, Chloe Lopez-Lee and Eileen Ruth Torres, all postdoctoral researchers in the Gan Laboratory during the study.<\/p>\n<p>Alzheimer\u2019s disease, which afflicts at least seven million adults in the United States, has long defied scientific efforts to understand its causes and develop effective treatments. Growing evidence suggests that tau\u2014not amyloid\u2014is the key driver of neurodegeneration and cognitive decline.<\/p>\n<p>What determines an individual\u2019s susceptibility or resistance to tau toxicity remains poorly understood. The Christchurch mutation, which protects against tau pathology and cognitive deterioration despite extensive amyloid buildup, offers an important clue.<\/p>\n<p>This rare mutation is found in the APOE gene encoding a cholesterol transport protein (apolipoprotein E), and was first discovered by a laboratory in Christchurch, New Zealand. In 2019, scientists studying a Colombian family with hereditary early-onset Alzheimer\u2019s, which typically strikes by age 50, reported that one family member, who had two copies of the Christchurch mutation, remained cognitively healthy into her 70s.<\/p>\n<p>Despite high brain amyloid, she exhibited low levels of tau. Subsequent research, mostly in mouse models, has confirmed the Christchurch mutation\u2019s beneficial effects\u2014but researchers still aren\u2019t sure how it exerts protection.<\/p>\n<p>In the new study, Dr. Gan\u2019s team engineered the Christchurch mutation into the APOE gene in mice that develop tau accumulation, and found that it protected the animals from hallmark Alzheimer\u2019s features\u2014including tau accumulation, synaptic damage, and disruptions in brain<\/p>\n<p>activity. These protective effects were traced to suppression of the cGAS-STING pathway, an innate immune signaling cascade normally activated in response to viral threat but is chronically activated in Alzheimer\u2019s disease.<\/p>\n<p>\u201cWe are particularly encouraged that this mutation ameliorates disease at the level of brain function, which has not been shown before,\u201d Dr. Naguib said.<\/p>\n<p>Dr. Gan and colleagues further discovered that the protective mechanism of the Christchurch mutation can be largely attributed to taming microglia, brain-resident immune cells. These cells and their inflammatory state in Alzheimer\u2019s have long been seen as potential drivers of the disease process.<\/p>\n<p>When the researchers treated mice with tau pathology using a small-molecule inhibitor of cGAS-STING signaling, they observed synapse-protecting effects and molecular changes in brain cells that closely resembled those seen with the protective mutation.<\/p>\n<p>With mounting evidence that cGAS-STING signaling contributes to disease progression, the team is now exploring its role in other neurodegenerative disorders and testing inhibitors on different animal models of these disorders.<\/p>\n<p>\u201cWe can\u2019t engineer the rare Christchurch mutation into people to prevent Alzheimer\u2019s,\u201d Dr. Gan said, \u201cBut targeting the same pathway it modulates\u2014cGAS-STING\u2014could offer a new therapeutic strategy for Alzheimer\u2019s, and potentially other neurodegenerative conditions.\u201d<\/p>\n<p>About this genetics and Alzheimer\u2019s disease research news<\/p>\n<p class=\"has-background\" style=\"background-color:#ffffe8\"><strong>Author: <\/strong><a href=\"http:\/\/neurosciencenews.com\/cdn-cgi\/l\/email-protection#85e7e4f5b1b5b5b1c5e8e0e1abe6eaf7ebe0e9e9abe0e1f0\" target=\"_blank\" rel=\"noreferrer noopener\">Barbara Prempeh<\/a><br \/><strong>Source: <\/strong><a href=\"https:\/\/med.cornell.edu\" target=\"_blank\" rel=\"noreferrer noopener\">Weill Cornell University<\/a><br \/><strong>Contact: <\/strong>Barbara Prempeh \u2013 Weill Cornell University<br \/><strong>Image: <\/strong>The image is credited to Neuroscience News<\/p>\n<p class=\"has-background\" style=\"background-color:#ffffe8\"><strong>Original Research: <\/strong>Closed access.<br \/>\u201c<a href=\"https:\/\/doi.org\/10.1016\/j.immuni.2025.05.023\" target=\"_blank\" rel=\"noreferrer noopener\">The\u00a0R136S\u00a0mutation in the\u00a0APOE3\u00a0gene confers resilience against tau pathology via inhibition of the cGAS-STING-IFN pathway<\/a>\u201d by Li Gan et al. Immunity<\/p>\n<p><strong>Abstract<\/strong><\/p>\n<p><strong>The\u00a0R136S\u00a0mutation in the\u00a0APOE3\u00a0gene confers resilience against tau pathology via inhibition of the cGAS-STING-IFN pathway<\/strong><\/p>\n<p>The Christchurch mutation (R136S) in the\u00a0APOE3\u00a0(E3S\/S) gene is associated with attenuated tau load and cognitive decline despite the presence of a causal\u00a0PSEN1\u00a0mutation and high amyloid burden in the carrier.<\/p>\n<p>However, the molecular mechanisms enabling the\u00a0E3S\/S\u00a0mutation to mitigate tau-induced neurodegeneration remain unclear.<\/p>\n<p>Here, we replaced mouse\u00a0Apoe\u00a0with wild-type human\u00a0APOE3\u00a0or\u00a0APOE3S\/S\u00a0on a tauopathy background.<\/p>\n<p>The\u00a0R136S\u00a0mutation decreased tau load and protected against tau-induced synaptic loss, myelin loss, and reduction in hippocampal theta and gamma power.<\/p>\n<p>Additionally, the\u00a0R136S\u00a0mutation reduced interferon responses to tau pathology in both mouse and human microglia, suppressing cGAS-STING pathway activation.<\/p>\n<p>Treating\u00a0E3\u00a0tauopathy mice with a cGAS inhibitor protected against tau-induced synaptic loss and induced transcriptomic alterations similar to the\u00a0R136S\u00a0mutation across brain cell types.<\/p>\n<p>Thus, suppression of the microglial cGAS-STING-interferon (IFN) pathway plays a central role in mediating the protective effects of\u00a0R136S\u00a0against tauopathy.<\/p>\n","protected":false},"excerpt":{"rendered":"Summary: A rare genetic mutation known as APOE3-R136S, or the \u201cChristchurch mutation,\u201d appears to protect against Alzheimer\u2019s disease&hellip;\n","protected":false},"author":3,"featured_media":10924,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[10263,827,815,11834,829,11835,912,831,159,67,132,68,11836],"class_list":{"0":"post-10923","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-alzheimers-disease","9":"tag-brain-research","10":"tag-genetics","11":"tag-inflammation","12":"tag-neurobiology","13":"tag-neuroinflammation","14":"tag-neurology","15":"tag-neuroscience","16":"tag-science","17":"tag-united-states","18":"tag-unitedstates","19":"tag-us","20":"tag-weill-cornell-university"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/114738793393941351","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/10923","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=10923"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/10923\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/10924"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=10923"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=10923"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=10923"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}